In conclusion, we determined that CB1R and CB2R agonists have inflammation-modulating and antifibrotic effects on normal human lung and IPF fibroblasts and human lung epithelial cells at specific concentrations. This evidence concerns the gene CNR1 and idiopathic pulmonary fibrosis.